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lVascular Risk Status as a Predictor of Later-Life
Depressive Symptoms: A Cohort Study
Mika Kivimäki, Martin J. Shipley, Charlotte L. Allan, Claire E. Sexton, Markus Jokela, Marianna Virtanen,
Henning Tiemeier, Klaus P. Ebmeier, and Archana Singh-Manoux
Background: Common etiology of vascular diseases and later-life depression may provide important synergies for prevention. We
examined whether standard clinical risk profiles developed for vascular diseases also predict depressive symptoms in older adults.
Methods: Data were drawn from the Whitehall II study with baseline examination in 1991; follow-up screenings in 1997, 2003, and 2008;
and additional disease ascertainment from hospital data and registry linkage on 5318 participants (mean age 54.8 years, 31% women)
without depressive symptoms at baseline. Vascular risk was assessed with the Framingham Cardiovascular, Coronary Heart Disease, and
Stroke Risk Scores. New depressive symptoms at each follow-up screening were identified by General Health Questionnaire caseness, a
Center for Epidemiologic Studies Depression Scale score16, and use of antidepressant medication.
Results: Diagnosed vascular disease (that is, coronary heart disease or stroke) was associated with an increased risk for depressive
symptoms, age- and sex-adjusted odds ratios from 1.5 (95% confidence interval 1.0–2.2) to 2.0 (1.4–3.0), depending on the indicator of
depressive symptoms. Among participants without manifest vascular disease, the Stroke Risk Score was associated with Center for
Epidemiologic Studies Depression Scale depressive symptoms before age 65 (age- and sex-adjusted odds ratio per 10% absolute change in
the score  3.1 [1.5–6.5]), but none of the risk scores predicted new-onset depressive symptoms in those aged 65 (odds ratios from .8
to 1.2).
Conclusions: These data suggest that public health measures to improve vascular risk status will influence the incidence of later-life
depressive symptoms via reduced rates of manifest vascular disease.
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T he vascular (or subcortical ischemic) depression hypothesissuggests a link between vascular pathology and later lifedepression (1–4). The mechanisms underlying this link are
hought to involvemicrodamage in small vessels in the frontal and
ubcortical regions of the brain, which are related to mood regula-
ion, and also hypothesized to contribute to the development of
epressive states (5). Epidemiological evidence shows vascular dis-
ases, such as myocardial infarction and stroke, increase the risk of
epression (6). Recently,Mast et al. (7) also found a composite score
ombining vascular diseases and vascular risk factors to predict
-year incidence of elevated depressive symptoms in individuals
ged 70 to 79, a finding replicated in another cohort of elders (8).
owever, few studies have been based on long follow-ups (1,2,9–
1), and it is not knownwhether vascular risk factors in the absence
fmanifest vascular diseasepredict later-life depression risk among
iddle-aged individuals. The clinical significance of establishing a
ink between vascular risk status and later-life depression is in rela-
ion to prevention of mental disorders.
Current guidelines on riskmanagement and treatment of vascu-
ar diseases recommend use of multifactorial risk prediction algo-
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doi:10.1016/j.biopsych.2012.02.005ithms (12–14), the Framingham risk scores being the most widely
sed and validated in clinical settings (15–17). These scores incor-
orate data on routinely measured risk factors, such as lipid levels,
lood pressure, and smoking, to calculate risk of vascular disease at
he individual level. The Framingham risk scores have been shown
o predict incident coronary heart disease (CHD), stroke, and cogni-
ive decline (15–18), but whether they also predict onset of depres-
ive symptoms at older ages is unknown.
In this study, we first examine the status of diagnosed vascular
isease as a risk factor for depressive symptoms. We hypothesize
hat this association exists; this is in agreement with the current
linical guidelines that recommend screening patients with vascu-
ar disease for depressive symptoms (19–21). The second objective
f this study is to examine whether in the absence of manifest
ardiovascular disease (CVD), subclinical vascular risk status, mea-
ured with standard clinical risk scores developed for assessing risk
f vascular disease, predicts depressive symptoms in older adults.
n increased risk of depressive symptoms among persons with an
dverse preclinical cardiovascular profilewould suggest that public
ealth measures to improve vascular risk status will also reduce
revalence of depressive symptoms.
ethods andMaterials
tudy Population
TheWhitehall II study is a prospective cohort studyof British civil
ervants established in 1985 to study associations between risk
actors, pathophysiological changes, and clinical disease (22). The
arget population was all London-based office staff, aged 35 to 55,
orking in 20 civil service departments on recruitment to the study
n 1985 to 1988 (phase 1). With a response of 73%, the cohort
onsisted of 10,308 employees (6895men and 3413women). Since
he phase 1 medical examination, follow-up examinations have
akenplace approximately every 5 years: phase 3 (1991 to 1993,n
815); phase 5 (1997 to 1999, n 7870); phase 7 (2003 to 2004, n
967); and phase 9 (2008 to 2009, n 6761). Phase 3 was the first
BIOL PSYCHIATRY 2012;72:324–330
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M. Kivimäki et al. BIOL PSYCHIATRY 2012;72:324–330 325time that all components of the Framingham risk algorithms were
measured, making it the baseline for the analyses we report here.
We use data from three screening cycles: from phase 3 to phase 5,
fromphase 5 to phase 7, and fromphase 7 to phase 9with phases 3,
5, and 7 providing baseline measures of vascular risk to assess
incidence of depressive symptoms at phases 5, 7, and 9 in the three
data cycles, respectively.
Ethical approval for theWhitehall II studywas obtained from the
University College LondonMedical School committee on the ethics
of human research; all participants provided written informed con-
sent.
Ascertainment of Coronary Heart Disease, Stroke, and
Nonvascular Chronic Conditions
Prevalent CHD (a history of myocardial infarction or angina),
stroke, and nonvascular chronic conditions were ascertained at
phases 3, 5, and 7. A history of angina was identified via question-
naire andwas corroboratedwithmedical records, by abnormalities
in a resting electrocardiogram (ECG), an exercise ECG, or a coronary
angiogram. Nonfatal myocardial infarction was defined following
the World Health Organization Multinational Monitoring of Trends
and Determinants in Cardiovascular Disease criteria (23) and ascer-
tained using data from five yearly medical examinations, hospital
records of acute ECGs, and use of cardiac enzymes. A history of
strokewas ascertained by self-reports (“Have you ever been told by
a doctor that you have had a stroke or transient ischemic attack?”
Yes/No). Nonvascular chronic condition in participants free of CHD
and stroke was identified by an affirmative response to a question:
“Do you have any longstanding illness, disability or infirmity?”
Assessment of Framingham Risk Factors
We used standard operating protocols to measure risk factors
for the Framingham general CVD risk score (sex, age, diabetes,
smoking, treated and untreated systolic blood pressure, total cho-
lesterol, high-density lipoprotein [HDL] cholesterol), CHD risk score
(sex, age, diabetes, smoking, systolic and diastolic blood pressure,
total cholesterol, HDL cholesterol), and stroke risk score (sex, age,
systolic bloodpressure, diabetes, smoking, prior cardiovascular dis-
ease, atrial fibrillation, left-ventricular hypertrophy, use of hyper-
tensive medications) at the baseline of each data cycle, i.e., phases
3, 5, and 7 (14–17). Venous bloodwas taken in the fasting state or at
least 5 hours after a light, fat-free breakfast. Serum for lipid analyses
was refrigerated at4°C and assayed within 72 hours. Cholesterol
was measured with the use of a Cobas Fara centrifugal analyzer
(Roche Diagnostics System, Nutley, New Jersey). High-density lipo-
protein cholesterol was measured by precipitating non-HDL cho-
lesterol with dextran sulfate-magnesium chloride using a centri-
fuge and measuring cholesterol in the supernatant. Participants
underwent an oral glucose tolerance test and new venous blood
sampleswere taken at 2 hours postadministration of a 75 g glucose
solution. Blood glucose was measured using the glucose oxidase
methodonaYSIMODEL2300STATPLUSAnalyzer (YSI Corporation,
Yellow Springs, Ohio; mean coefficient of variation: 1.4%–3.1%).
Diabetes was defined by fasting glucose 7.0 mmol/L or 2-hour
postloadglucose11.1mmol/L, reporteddoctor diagnoseddiabe-
tes, or use of diabetes medication (24). We measured systolic and
diastolic blood pressure twice in the sitting position after 5minutes
rest with a Hawksley random-zero sphygmomanometer (phases 3
and 5) (Lynjay Services Ltd., Worthing, United Kingdom) and
OMRON HEM 907 (phase 7) (Omron, Milton Keynes, United King-
dom), the average of two readings used in the analysis. Atrial fibril-
lation was identified on the Glasgow 12-lead electrocardiogram
analysis program combined with manual review (Prof. P. Macfar- Tane, University ofGlasgow,UnitedKingdom). Limb lead electrocar-
iograms were classified according to the Minnesota code (25),
ith tall R waves (codes 3-1 to 3-3) used to reflect left ventricular
ypertrophy. Information on smoking and use of antihypertensive
rugs and lipid-lowering medication was requested at phases 3, 5,
nd 7.
The validity of the Framingham risk scores as measures of vas-
ular risk was supported in our study, as they strongly predicted
ncidence of subsequent (manifest) vascular disease. Age- and sex-
djusted odds ratio for 10% increment in risk was 2.84 (95% confi-
ence interval [CI] 1.66–4.88) for the stroke risk score-incident
troke association and 2.25 (95% CI 1.92–2.65) for the CHD risk
core-incident CHD association. The corresponding odds ratios for
he associations of CVD risk score with stroke and CHD were 1.34
95% CI 1.11–1.62) and 2.14 (95% CI 1.85–2.48), respectively.
ssessment of Depressive Symptoms
Weused three indicators (or proxymeasures) to identify persons
ith depressive symptoms. First, participants responded to the
elf-administered 30-item General Health Questionnaire (GHQ) at
hases 3, 5, 7, and 9, a screening instrument designed for and
idely used in population-based surveys and trials (26). Each ques-
ionnaire item enquires about a specific symptom, with response
ategories scored as either 1 or 0 to indicate whether the symptom
s present. Total score of 5 or more led to individuals being defined
s GHQ-symptom cases and scores 0 to 4 as noncases (27). Al-
hough the GHQ was originally designed to assess depressive and
nxiety symptoms, a recent population-based study showed GHQ
aseness to be sensitive (84%) and specific (84%) in detecting dys-
hymia ormajor depressive disorder, as indicatedby theComposite
nternational Diagnostic Interview (28). The GHQ has also been
alidated at baseline against a clinical interview schedule in the
hitehall II study, with acceptable sensitivity (73%) and specificity
78%) (27). In a more recent validation using a subgroup of 274
articipants aged 58 to 70 in 2010, the sensitivity and specificity of
HQ symptom caseness against diagnosed depressive episodes
ased on a structured psychiatric interview were 80% and 81%,
espectively.
Second, at phases 7 and 9, depressive symptoms were also
ssessed using the Center for Epidemiologic Studies Depression
cale (CES-D) (note that CES-Dwas not included in earlier screening
hases of our study) (29). The 20 items of the CES-Dmeasure symp-
oms associated with depression; participants are asked to score
he frequency of occurrence of specific symptoms during the pre-
ious week on a four point scale (0  less than one day, 1  1–2
ays, 2 3–4 days, and 3 5–7 days). These items are summed to
ield a total score between 0 and 60, with participants scoring16
efined as having CES-D depressive symptoms (30). In a validation
tudy of 274 Whitehall II participants, sensitivity and specificity
ere 89% and 86%, respectively, for CES-D depressive symptoms
sing a structured psychiatric interview as the criterion.
Third, at phases 3, 5, 7, and 9, participants were asked whether
hey had taken any medication in the past 14 days and, if so, to
rovide thenameof themedication.Medicationswere codedusing
ritish National Formulary codes to define antidepressant medica-
ion use (codes: 040301–040304) (31).
tatistical Analysis
All data analyses were performed with SAS version 9.2 (SAS
nstitute Inc., Cary, North Carolina). As the two study questions
ddressed in this investigation require different population sam-
les, we describe the analytic samples and procedures in two parts.
he analyses combine men and women, as there was no evidence
www.sobp.org/journal
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wto suggest that the associations of vascular disease and the Fra-
mingham risk scores with subsequent depressive symptoms dif-
fered by sex (all p values for sex interaction  .07). The analysis
trategy for repeateddata cycles followed that used in the Framing-
am study (32).
Analysis 1: Manifest Vascular and Nonvascular Disease as a
redictor of Depressive Symptoms. Participants were eligible
or these analyses if they completed thehealthquestionnaire at any
wo consecutive phases between phase 3 and phase 9 and had no
issing data on disease status at the corresponding baseline
hases (see Supplement 1 for a detailed description of sample
election). For comparison, we examined the association between
onvascular diseases as a predictor of depressive symptoms.
riefly, at each of the three data cycles, we excluded participants
ho had prevalent or previous depressive symptoms at baseline or
issing data on depressive symptoms at baseline or at follow-up.
ach participant could contribute to the outcome (onset of depres-
ive symptoms) only once. The analysis of GHQ symptoms was
ased on 5230, 4029, and 3571 participants in the first, second, and
hird data cycles, a total of 12,830 person observations. The corre-
ponding numbers for the analysis of antidepressant use were
326, 6405, and 5890, respectively (a total of 19,621 person obser-
ations). The analysis on CES-D depressive symptoms (measured
nly at phases 7 and 9) was based on 4509 participants (or person
bservations).
We used logistic regression to study the age- and sex-adjusted
ssociations of baseline vascular disease (CHD or stroke) and non-
ascular disease with GHQ symptoms at follow-up across each of
he three data cycles among participants without GHQ symptoms
t the baseline of the cycle. We repeated this analysis with onset of
HQ symptoms before age 65 and at age 65 or later in separate
nalyses. We also repeated these analyses with onset of CES-D
epressive symptoms and use of antidepressants over the fol-
ow-up as the outcomemeasures.
Analysis 2: FraminghamRisk Scores as Predictors ofDepres-
ive Symptoms in Participants Free of Vascular Diseases. Par-
icipants were eligible for these analyses if they completed the
ealth questionnaire and attended the screening at any two con-
ecutive phases between phases 3 and 9 (Supplement 1). At the
aseline of each of the three screening cycles, we excluded partici-
ants who had prevalent depressive symptoms at baseline, those
ith prevalent CHD or stroke, and those with missing data on risk
actors for the Framingham scores at baseline or on depressive
ymptoms at baseline or follow-up. For the second and third
creening cycles, we additionally excluded those with previous de-
ressive symptoms before the baseline of the cycle. In the analysis
or GHQ symptoms, there were 4687, 2956, and 3013 participants
or the three data cycles (a total of 10,656 person observations). In
he analysis of antidepressant use, the corresponding numbers of
articipants were 6339, 4474, and 4889 (15,702 person observa-
ions). The analyses for CES-D depressive symptoms was based on
786 participants (or person observations).
We constructed Framingham CVD, CHD, and stroke risk scores
or each participant and used logistic regression to examine the
ssociation of each risk score at baselinewith depressive symptoms
t follow-up. Crude, age- and sex-adjusted, and multivariably ad-
usted odds ratios and 95% confidence intervals per 10% absolute
ncrease in risk score were calculated. In the analysis of GHQ symp-
oms, the sample was large enough to detect, with 90% power at a
ignificance level of .05, an odds ratio of 1.14 for a 10% increase in
he Framingham CVD risk score. For depressive symptoms defined
y CES-D and antidepressant medication, the corresponding odds
atios were 1.40 and 1.24, respectively. t
ww.sobp.org/journalAnalysis 3: Subsidiary Analysis. To more comprehensively
xclude participantswith prevalent or previous depression at base-
ine, we examined the associations between the Framingham risk
cores at phase 5 and CES-D depressive symptoms at phase 7 or
hase 9 in a subcohort (n 1635) free of depressive symptoms (i.e.,
ithoutGHQsymptomsandantidepressantuse) andalsowithout a
istory of depression, based on a psychiatric interview completed
t phase 5: the University of Michigan version of the Composite
nternational Diagnostic Interview (33,34). In addition, the effect of
range of baseline characteristics (Supplement 1) on these associ-
tions was examined using multivariable adjustments.
esults
Differences between the analytic sample and the excluded par-
icipants were generally small (Table S1 in Supplement 1). Com-
aredwith those included, participants excluded from the analyses
ere more likely to be women, nonwhite, and current smokers,
lthough other characteristics were similar in the two groups.
cross the 5-year data cycles, 12.1% of participants without GHQ
ymptomsdeveloped such symptoms, 4.6%of thosewithoutCES-D
epressive symptoms had such symptoms at follow-up, and 2.1%
f those not on antidepressant treatment started suchmedication.
f the cases of GHQ symptoms, 5.4% used antidepressant medica-
ion, the corresponding proportion being 9.2% for those with
ES-D depressive symptoms. Of participants with GHQ symptoms,
7.4% also had CES-D depressive symptoms (Pearson correlation at
hase 7 r  .64, p  .001). Conversely, among participants with
ES-D depressive symptoms, 59.9% also had GHQ symptoms.
anifest Vascular and Nonvascular Diseases as Predictors of
epressive Symptoms
Table 1 shows results of the association of prevalent manifest
ascular and nonvascular diseases with indicators of depressive
ymptoms. Age- and sex-adjusted odds ratios for new-onset GHQ
ymptoms, CES-D depressive symptoms, and use of antidepres-
ants were 1.75, 2.02, and 1.50 for participants with prevalent CHD
r stroke compared with those without these conditions. The asso-
iationsof long-termnonvascular disease (excludingcomorbid vas-
ular disease) with indicators of subsequent depressive symptoms
ere similar (range of odds ratios between 1.53 and 1.88).
ramingham Risk Scores as Predictors of Depressive
ymptoms
Table 2 presents age- and sex-adjusted odds ratios for associa-
ions of Framingham risk scores with subsequent depressive symp-
oms in those freeofmanifest vascular disease. Higher Framingham
isk scores were associatedwith higher odds for new-onset depres-
ive symptoms before age 65 as assessed with CES-D (odds ratios
etween 1.42 and 3.09, depending on the score). Higher CHD risk
core was additionally associated with greater odds of starting an-
idepressant treatment. In contrast, none of the vascular risk scores
ere associated with new-onset GHQ symptoms before the age of
5 (odds ratios between 1.03 and 1.17). Furthermore, none of the
ascular risk scores had statistically significant associations with
HQ symptoms, CES-D depressive symptoms, or antidepressant
edication use after the age of 65 (all p values .35). In unadjusted
nalyses, no evidence of a significantly greater risk of depressive
ymptoms before or after the age of 65 among personswith higher
ascular risk scores was found (Tables S3 and S4 in Supplement 1).
or example, unadjusted odds ratio per 10% increase in the stroke
isk score was 1.56 (95% CI .72–3.39) for CES-D depressive symp-
oms before the age of 65.
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After adjustment formultiple covariates (age, sex,marital status,
education, socioeconomic status, retirement, cognitive impair-
ment, body mass index, alcohol consumption, menopausal status
[women], and nonvascular chronic condition), the association be-
tween vascular disease and subsequent CES-D depressive symp-
toms remained in participants with no prevalent or previous de-
pressive episodes, as indicated by the Composite International
Diagnostic Interview (Table 3). Higher stroke risk score was associ-
ated with higher odds of onset of CES-D depressive symptoms
before (odds ratio 2.30, 95% CI 1.03–5.13), but not after, the age 65.
The CVD and CHD risk scores were not associated with subsequent
depressive symptoms.
Table 1. Association of Prevalent Vascular (Coronary Heart Disease or Strok
Depressive Symptoms
Predictor na
Prevalent CHD/Stroke
No 12166
Yes 664
Long-Standing Illness (Nonvascular)d
No 7095
Yes 4884
Prevalent CHD/Stroke
No 4137
Yes 372
Long-Standing Illness (Nonvascular)d
No 1787
Yes 2293
Prevalent CHD/Stroke
No 18430
Yes 1191
ong-Standing Illness (Nonvascular)d
No 10088
Yes 7810
CES-D, Center for Epidemiologic Studies Depression Scale; CHD, corona
aNumber of person observations.
bOdds ratios are adjusted for age and sex.
cAcross three data cycles (from phase 3 to phase 5; from phase 5 to phas
dExcluding participants with vascular disease (CHD or stroke).
eFrom phase 7 to phase 9 (one data cycle).
able 2. Association Between Framingham Risk Scores (per 10% Increase)
Outcome Predictora
Age at Onse
nb
n of
Cases
Od
(9
New-Onset GHQ
Symptoms
CVD risk score 9445 1184 1.03 (
CHD risk score 9445 1184 1.12 (
Stroke risk score 9445 1184 1.17 (
New-Onset CES-D
Depressive
Symptoms
CVD risk score 1916 59 1.42 (
CHD risk score 1916 59 1.44 (
Stroke risk score 1916 59 3.09 (
Starting
Antidepressant
Treatment
CVD risk score 14,045 283 1.19 (
CHD risk score 14,045 283 1.24 (
Stroke risk score 14,045 283 1.06 (
CES-D, Center for Epidemiologic StudiesDepression Scale; CHD, coronary
Health Questionnaire.
aOdds ratio per each 10% increase in risk score adjusted for age and sex.
bNumber of person observations.iscussion
This longitudinal study of British adults shows that manifest
ardiovascular disease (CHD and stroke) is associated with in-
reased riskofdepressive symptoms. Therewasalso someevidence
o suggest an association between higher Framingham stroke risk
core and increased onset of depressive symptoms before the age
f 65 years. However, the vascular risk scores did not predict later-
ife depressive symptomsamongpersonswithnomanifest vascular
isease or history of depression. This finding was based on data
rom three different vascular risk prediction algorithms—the Fra-
inghamCVD, CHD, and stroke scores—anddepressive symptoms
easured using two survey instruments and information on use of
ntidepressant medication.
d Nonvascular Disease (Long-Standing Illness) with Subsequent Onset of
of Cases Odds Ratiob (95% CI) p Value
utcome: New-onset GHQ symptomsc
1461 1.0
96 1.75 (1.39, 2.21) .001
779 1.0
662 1.53 (1.37, 1.72) .001
utcome: New-onset CES-D depressive symptomse
253 1.0
41 2.02 (1.42, 2.98) .001
76 1.0
177 1.88 (1.41, 2.47) .001
utcome: Starting antidepressant treatmentc
369 1.0
34 1.50 (1.04, 2.16) .03
153 1.0
205 1.80 (1.45, 2.23) .001
rt disease; CI, confidence interval; GHQ, General Health Questionnaire.
rom phase 7 to phase 9).
ubsequent Onset of Depressive Symptoms Before and After Age 65
Age at Onset65 (Later-Life)
tio
I) p Value nb
n of
Cases
Odds Ratio
(95% CI) p Value
.15) .59 1211 89 .97 (.79, 1.20) .80
.25) .06 1211 89 1.03 (.78, 1.36) .83
.64) .35 1211 89 .83 (.54, 1.27) .38
1.96) .04 870 39 1.09 (.80, 1.47) .60
2.03) .04 870 39 1.00 (.63, 1.59) .99
6.47) .003 870 39 .83 (.43, 1.58) .57
.44) .07 1657 32 1.16 (.85, 1.58) .35
1.51) .04 1657 32 1.08 (.68, 1.71) .75
.97) .85 1657 32 .93 (.48, 1.79) .83
t disease; CI, confidence interval; CVD, cardiovascular disease; GHQ,Generale) an
n
O
O
O
ry hea
e 7; fand S
t65
ds Ra
5% C
.92, 1
.99, 1
.84, 1
1.03,
1.02,
1.48,
.99, 1
1.02,
.57, 1
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wThe association between manifest vascular disease and in-
creased risk of depressive symptoms is in agreement with previous
studies (6,34–38). The onset of depressive symptoms in those with
manifest vascular disease may be the result of vascular pathology,
but it is also possible that the diagnosis of a pernicious chronic
disease per se and its impact on quality of life induces depressed
mood. The second of these explanations is supported in our study
by results showing an equally strong and consistent association
between long-term nonvascular diseases (excluding vascular co-
morbidity) and the risk of subsequent depressive symptoms. In-
deed, depressive symptoms in the elderly may be a correlate of
various disabling conditions (e.g., chronic lungdisease, loss of hear-
ing, and loss of vision) (4) in addition to diseases of a vascular origin.
Physiological impact of both vascular and nonvascular disease on
inflammatory, endocrine, and immune systems may increase vul-
nerability to depressive symptoms (39,40).
Validated multifactorial risk prediction algorithms, such as the
Framingham risk scores, and objective measures of atherosclerosis
are used to determine preclinical vascular risk status (41,42). To the
best of our knowledge, this is the first large-scale study of amiddle-
aged population on the association between Framingham risk
scores and later-life depressive symptoms. These scores alone did
not predict the onset of depressive symptoms at age 65 or older,
although the stroke risk score was associated with the onset of
depressive symptomsat younger ages. These resultswereapparent
in age- and sex-adjusted and multivariably adjusted models but
were weaker in unadjusted models, possibly because greater age
and male sex increased the stroke risk score but were related to a
lower risk of depressive symptoms in that age range. The associa-
Table 3. Association of Prevalent Disease and Framingham Risk Scores at P
Phase 9 Among Participants with No Current or Previous Depressive Sympt
Based on Psychiatric Interview
Predictor
n of
Participants
n of
Cases
Prevalent CHD/Stroke
No 1541 150
Yes 94 15
Long-Standing Illness (Nonvascular)c
No 910 78
Yes 598 70
CVD Risk Scorec
Per 10% increase 984 106
CHD Risk Scorec
Per 10% increase 984 106
Stroke Risk Scorec
Per 10% increase 984 106
CVD Risk Scorec
Per 10% increase 377 28
CHD Risk Scorec
Per 10% increase 377 28
Stroke Risk Scorec
Per 10% increase 377 28
CES-D, Center for Epidemiologic Studies Depression Scale; CHD, corona
aOdds ratios are adjusted for age and sex.
bOdds ratios are adjusted for age, sex, marital status, education, socio
consumption, andmenopausal status forwomen.Analysesof vascular diseas
condition.
cExcluding participants who have diagnosed vascular disease.tionbetween stroke risk anddepressive symptomswarrants further v
ww.sobp.org/journalesearch, as it raises the possibility that cerebrovascular rather than
ardiovascular risk status may act as an early marker of depression
isk.
A few previous studies have examined the longitudinal associa-
ion between overall vascular risk and later-life depression using
ther indicators of vascular risk status. In the Health, Aging and
ody Composition study of adults aged 70 or higher, a score com-
ining selected vascular risk factors (body mass index, metabolic
yndrome, smoking, and ankle arm index) and vascular diseases
redicted higher 2-year incidence of elevated depressive symp-
oms (7). However, the extent to which this association was attrib-
table to vascular risk factors alone is difficult to assess in such a
tudydesign. In the Rotterdamstudyof older adults followedup for
years (11), none of the objective atherosclerosis measures was
inked with subsequent depression. This null finding was evident
rrespective of whether assessment of depression was based on
ES-D or a clinical diagnosis obtained from a psychiatric interview
11). Similarly, in the Leiden 85 prospective cohort study, ratings
f generalized atherosclerosis were not associated with depressive
ymptoms (43).
In light of this study, as well as data from previous longitudinal
tudies (11,43), unfavorable preclinical vascular status is not an
ndependent risk factor for later-life depressive symptoms. It is pos-
ible that the hypothesized vascular origin of depression in older
dults is driven by severe clinical vascular pathology and therefore
pparent only in relation to manifest disease or that vascular dis-
ase is a correlate rather than causeof depressive symptoms in later
ife (44–47). Later-life depressive symptoms may also be a hetero-
eneous multietiological disorder and depression resulting from
5 with Subsequent Onset of CES-D Depressive Symptoms at Phase 7 or
No Current or Previous Antidepressant Use, and No History of Depression
s Ratioa (95% CI) p Value Odds Ratiob (95% CI) p Value
ome: New-onset depressive symptoms—all ages
0 1.0
75 (.97, 3.15) .06 1.82 (1.00, 3.31) .05
1.0 1.0
41 (1.00, 1.98) .05 1.40 (.99, 1.99) .06
ome: New-onset depressive symptoms before age 65
25 (.90, 1.75) .19 1.27 (.89, 1.81) .19
96 (.64, 1.46) .86 .96 (.61, 1.49) .84
54 (1.19, 5.43) .02 2.30 (1.03, 5.13) .04
ome: New-onset depressive symptoms at age65
86 (.54, 1.37) .53 1.03 (.65, 1.65) .89
56 (.28, 1.12) .10 .71 (.35, 1.44) .33
37 (.72, 2.60) .33 1.30 (.62, 2.72) .37
rt disease; CI, confidence interval; CVD, cardiovascular disease.
omic status, retirement, cognitive impairment, body mass index, alcohol
risk scores aspredictorswere additionally adjusted for nonvascular chronichase
oms,
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M. Kivimäki et al. BIOL PSYCHIATRY 2012;72:324–330 329disorders in older people. This would lead any association between
vascular risk factors and overall later-life depressive symptoms to
be diluted, an explanation in keeping with a recent prospective
population-based study that showed no significant association be-
tween later-life depression and cerebrovascular pathology in post-
mortem data (48).
Limitations
There are caveats to the results reported here. We measured
depressive symptoms using validated instruments, such as the
General Health Questionnaire and CES-D, and information on pre-
scribed antidepressant medication use (26,29,49). These instru-
ments are not designed to make a psychiatric diagnosis of first or
recurrentmajor depression (26,29); theydefinedonlypartially over-
lapping case populations and some misclassification occurred be-
cause antidepressants are also prescribed for conditions other than
depression. Nevertheless, the associations of manifest CHD and
stroke with depressive symptoms in our study are in agreement
with previous research linking vascular disease to depressive symp-
toms and clinical depression (4,35–38,44). Furthermore, in a valida-
tion study of 274 elderly participants from our cohort, sensitivity
and specificity of thequestionnairemeasureswithdepressiondiag-
nosed based on structured psychiatric interview as the criterion are
high, almost 90% for CES-D depressive symptoms and approxi-
mately 80% for GHQ symptoms.
Despite a high response to the survey (range 66% to 88%) at the
successive data collection phases, loss to follow-up accumulated
over the extended follow-up, as is inevitable in long-term prospec-
tive studies. However, differences between the included and ex-
cluded participants were generally small. Our study is based on an
occupational cohort, which, by its very nature, is healthier than the
general population, so the range of vascular risk scores and the
range of depressive symptom measurements are likely to be nar-
rower. This being the case, the associations between the Framing-
ham risk scores and depressive symptoms reported here could
underestimate the strength of associations in the general popula-
tion, although similar associations between manifest vascular dis-
ease and depressive symptoms in the present dataset and those
from thegeneral population suggest that our estimates are likely to
be fairly accurate. Due to the relatively low numbers of depressive
symptom cases in the present data, we cannot detect weak associ-
ations between vascular risk scores and later-life depressive symp-
toms.
Clinical Implications
These results suggest that public health measures to improve
vascular status will influence the incidence of later-life depression,
primarily via reduced rates of manifest vascular disease. Our find-
ings on diagnosed vascular disease support current clinical guide-
lines to screen patients with coronary heart disease or stroke for
depressive symptoms. However, although the stroke risk score was
associated with depressive symptoms before the age of 65, we
found little evidence to suggest that standard clinical information
on preclinical vascular risk statuswould be helpful in the prediction
of depressive symptoms after the age of 65 years. Thus, extending
screening of incident later-life depression to include those identi-
fied as having a high risk of developing vascular disease was not
supported by this study.
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